Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + R-GCD in R/R DLBCL and High-Risk Follicular Lymphoma
NCT04156828Phase 1Terminated
- Sponsor
- University of Washington
- Start
- Mar 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), sponsored by University of Washington. Primary endpoint: Dose Limiting Toxicity at 21 days. Started Mar 2020; status: terminated.
02
Drugs
copanlisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04156828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156828.